期刊文献+

乙型肝炎血清学指标与肝组织纤维化分期的相关性 被引量:3

Analysis of correlation of serum markers and liver fibrosis stage in patients with chronic hepatitis B
下载PDF
导出
摘要 目的:探讨乙型肝炎患者血清学指标与肝组织纤维化病理学分期的相关性。方法:对214例乙型肝炎患者肝组织活检后进行常规病理检查,同时检测其血清肝纤维化指标、生化指标、凝血指标。比较分析各项检测项目与肝组织纤维化分期之间的相关性。结果:肝纤维化病理学分期与透明质酸、层黏连蛋白、Ⅳ型胶原、Ⅲ型前胶原等血清学指标之间的差异均有统计学意义(P<0.01)。结论:透明质酸、层粘连蛋白、Ⅳ型胶原、Ⅲ型前胶原等血清学检测项目的联合检测,可有效地辅助诊断乙型肝炎患者肝纤维化程度,并预测肝纤维化发展的趋势。 Objective: To investigate the correlation of serum markers and liver fibrosis pathological stage in patients with cbronic hepatitis B. Methods:The routine pathological examination of liver biopsy was tested in 214 cases of hepatitis B patients, the serum markers of liver fibrosis and liver function parameters, blood coagulation index and HBV-DNA level were also measured. The correlation of the test items and liver fibrosis stage was discussed. Results: There were statistical differences about hyaluronic acid, laminin, Ⅳ collagen, Ⅲ procollagen and other 10 test items with pathological stages of liver fibrosis (P 〈 0.01 ). Conclusions: Hyaluronie acid, laminin, collagen IV, collagen Ⅲ and other serum test could be effective in diagnosis of hepatitis B patients with liver fibrosis, and they can predict the trend of liver fibrosis.
出处 《蚌埠医学院学报》 CAS 2012年第6期690-692,695,共4页 Journal of Bengbu Medical College
关键词 乙型肝炎 肝纤维化 血清学指标 hepatitis B liver fibrosis serum indicators
  • 相关文献

参考文献9

二级参考文献54

  • 1病毒性肝炎防治方案(试行)[J].中华传染病杂志,1995,13(4):241-247. 被引量:1767
  • 2白石山,李秀霞,杨守昌,汪能平,骆抗先.血清透明质酸、Ⅲ型前胶原、板层素及脯氨酸肽酶水平与肝纤维化的关系[J].中华肝脏病杂志,1997,5(2):72-73. 被引量:52
  • 3Parson CJ,BradfordBU.Pan CQ,et al.Antifibrotic effects of atissue inhibitor of metalloproteinase-1 antibody on established liver fibros in rats (J).Hepatology,2004,40(5):1106.
  • 4Boker KH,Pehle B,Steinmetz C.et al.Fissue inhihitor of metal-loproteinases in liver and serum/plasma in chronic active hepatitisc and HCV –inducedcirrhosis[J].Hepato-Gastroenterology,2000,47(33):812.
  • 5Colonno RJ,Genovesi EV,Medina I,et al.Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in thewoodchuckmodel of chronic hepatitis infection[J].J InfectDis,2001,184(10):1236.
  • 6Marion PL,SalazarFH,W intersMA,eta.l Potentefficacy of entecavir(BMS-200475)in a duckmodel of hepatitisB virus replication[J].Antimicrob Agents Chemother,2002,46(1):82.
  • 7Ulander JG,Colonno RJ,Sidwell RW,et al.Characterization of antiviral activity of entecavir in transgenicmice expressing hepatitis B virus[J].AntiviralRes,2003,59(3):155.
  • 8YamanakaG,W ilsonT,InnaimoS,eta.l Metabolic studieson BMS-200475,a new antiviral compound active against hepatitis B virus[J].Antimicrob AgentsC hemother,1999,43(1):190.
  • 9Chang TT,Gish RG,Man DR.Et al.A comparison of Entecavir and Lamivudine for HBeAg-positive chronic hepatitis B[J].NEW ENGL J MED,2006,354(10):1001.
  • 10Gish RG,Lok AS,Chang TT,et al.Entecavir therapy for up to 96 weeks in patients with HBeAg-Positive ChronicHepatitis B[J].Gastroenterology,2007,133:1437.

共引文献132

同被引文献36

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部